TactiCath Quartz force-sensing ablation catheter developed by Endosense has obtained a CE mark approval.
The catheter was developed with an aim to improve the safety and efficacy of catheter ablation while treating cardiac arrhythmias. The catheter was first used by well known physicians at three centers spread all over Europe.
The TactiCath Quartz provides a number of practical and technical improvements to the electrophysiology lab. Significant innovations of the TactiCath Quartz include:
- A new force sensor that enables providing increased precision and stability and avoiding requirement for pre-procedure calibration.
- A graphical interface that is user friendly.
- Improved digital output and signal processing that enables providing connectivity with lad equipment e.g. imaging devices.
- A small equipment footprint.
A new discovery to the TactiCath Quartz catheter is a breakthrough Lesion Index (LSI) parameter that is used in catheter ablation procedures in order to provide an improved lesion quality in real-time. The LSI conceived by Endosense is an algorithm that enables correlating lesion formation with contact force, radiofrequency power and ablation time. Reconnection risks that may occur after pulmonary vein isolation are predicted by the LSI with efficient statistical significance.
Jan Keltjens, President and Chief Executive Officer of Endosense, refers to the TactiCath Quartz as a third generation device that will highlight the significance of force-sensing with its improved performance and easy operation process. He added that the TactiCath Quartz has also been approved for treating supraventricular tachycardia (SVT) and atrial fibrillation (AF).
The TactiCath Quartz and the TactiSys system are both available in Europe through BIOTRONIK which is a distribution partner of Endosense.
Source: http://www.endosense.com/